Monthly Archives: May 2012

The manhood makeover: The rise of the penis enlargement

Posted: Published on May 15th, 2012

A vast painting covers the wall above a marble mantelpiece on which rests a human skull. It depicts Maurizio and Roberto Viel, who are twin plastic surgeons, and a nude woman whose breasts they have augmented. The imposing work, called Creation, greets patients at the brothers clinic on Harley Street in London. Increasingly these patients are men and, increasingly, they come in search of a larger penis. Achieve massive girth; Get your giant tool now: These are genuine subject lines from spam emails that invade our inboxes, offering quack solutions to men who feel small. As the prevalence of porn as well as the increasing exposure of crotches and more on billboards (think David Beckhams pants ads) helps to fuel a rising sense of inadequacy among many men, penis enlargement has become a growth business. The problem for those who would make penises larger, however, is that, much more than breasts, for example, they have evolved to withstand great stress and changes in size. They resist almost all attempts to make them permanently bigger. Roberto Viel says he has overcome these challenges, and performs about 200 penoplasty operations a year. Sitting at his desk, he pulls out a gold-nibbed pen … Continue reading →

Posted in Penis Enlargement | Comments Off

Globales Kompetenzzentrum für Windkraft in Dänemark

Posted: Published on May 15th, 2012

Leverkusen (P) - Die Bayer Material Science AG (BMS), Leverkusen, will an seinem Standort Otterup in Dnemark ein globales Kompetenz- und Entwicklungszentrum fr Windenergie einrichten. Es soll die weltweiten Aktivitten lenken und koordinieren, mit denen moderne Werkstoffe fr Anwendungen im Bereich der Windenergie entwickelt werden. Leiter des neuen globalen Kompetenzzentrums ist Kim Harnow Klausen. Er bernimmt die Aufgabe zustzlich zu seiner Funktion als Geschftsfhrer von Bayer MaterialScience A/S in Dnemark. Das Projekt soll verdeutlichen, mit welchem Engagement das Unternehmen innovative und nachhaltige Materialien und Technologien fr die Energieerzeugung aus regenerativen Quellen entwickelt. Im gesamten Produktportfolio von BMS angefangen von Polyurethanen ber Polycarbonate bis hin zu Lacken, Klebstoffen und Spezialitten soll das Zentrum die Entwicklungskapazitten bndeln und die Expertise von Forschungs- und Entwicklungsteams aus aller Welt vereinen. Zu diesem Zweck plant BMS am Standort seines Polyurethan-Systemhauses in Otterup eine Erweiterung des Portfolios um Lsungen fr Windkraft-Anwendungen. Dazu gehren Rohstoffe fr Lacke und Klebstoffe, Kohlenstoff-Nanorhrchen, Matrixwerkstoffe und Produktionsverfahren fr Rotorbltter, auerdem Faserverbundstoffe und Produktionsverfahren fr die Triebwerksgondeln. Eine der jngsten Technologieentwicklungen in diesem Bereich stellt ein Polyurethan-Hybridsystem von Bayer dar, mit dem Rotorbltter im Vakuum-Infusionsverfahren hergestellt werden knnen. Hierdurch lieen sich die Kosten der Energieerzeugung deutlich verringern. Standort in Dmemark bringt deutliche … Continue reading →

Posted in Cheap Pharmacy | Comments Off

Furiex Enters Agreement For Priligy Product Rights

Posted: Published on May 15th, 2012

DOW JONES NEWSWIRES Johnson & Johnson's (JNJ) Alza Corp. and Janssen Pharmaceutica N.V. units have agreed to transfer worldwide rights for the premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals Inc. (FURX). Separately, Furiex said it will license to Menarini Group rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain full development and commercialization rights in the U.S., Japan and Canada. Under the agreement with Menarini, Furiex will be eligible to receive a $15 million payment upon closing, up to $20 million in regulatory and launch milestones and up to $40 million in sales-based milestones, plus tiered royalties on product sales ranging from the mid-teens to mid-twenties on a percentage basis. Priligy is currently marketed by Janssen for the treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America and is approved in 43 countries worldwide. Janssen will continue to manufacture and manage certain clinical and regulatory activities related to Priligy for a defined period after the closing date of its agreement with Furiex. Shares closed at $14.23 Monday and were halted after hours. The stock is off 15% over the past three months. -By Nathalie … Continue reading →

Posted in Premature Ejaculation | Comments Off

Furiex Pharmaceuticals and Menarini Announce License Agreement for Priligy®

Posted: Published on May 15th, 2012

MORRISVILLE, N.C. & FLORENCE, ITALY--(BUSINESS WIRE)-- Furiex Pharmaceuticals, Inc. (NASDAQ: FURX - News) and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain full development and commercialization rights in the United States, Japan and Canada. Currently, Priligy is marketed for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America, while it is approved for that indication in 43 countries worldwide. Under the terms of the agreement, Furiex will be eligible to receive a $15 million payment upon closing, up to $20 million in regulatory and launch milestones and up to $40 million in sales-based milestones, plus tiered royalties on product sales ranging from mid-teens to mid-twenties in percentage terms. Menarini will assume responsibility for commercialization activities in the licensed territories and will fund ongoing clinical trials. June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex, stated, We are extremely pleased to partner with Menarini and are confident that our experience and skills, coupled with the global presence and pharmaceutical experience of Menarini, should expand … Continue reading →

Posted in Premature Ejaculation | Comments Off

Furiex Pharmaceuticals Announces Agreement to Transfer Priligy® Product Rights

Posted: Published on May 15th, 2012

MORRISVILLE, N.C.--(BUSINESS WIRE)-- Furiex Pharmaceuticals, Inc. (NASDAQ: FURX - News) announced that it has entered into an agreement with ALZA Corporation and Janssen Pharmaceutica, N.V. whereby ALZA and Janssen will transfer worldwide rights for Priligy to Furiex. Currently Priligy is marketed by Janssen for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America, while it is approved for that indication in 43 countries worldwide. To ensure a smooth transition, Janssen will continue to manufacture and manage certain clinical and regulatory activities with respect to Priligy for a pre-defined period after the closing date of the agreement. Janssen will continue to make Priligy available to patients until the Marketing Authorizations are transferred, at which time commercialization of the product will transition to Furiex or its licensee. Priligy is the only treatment for premature ejaculation that has received regulatory approval, and we appreciate Janssens commitment for a smooth transition so that patients can continue to receive this important medicine, said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. Under the agreement, Janssen will transfer to Furiex registration and commercialization activities for Priligy worldwide. Janssen will remain the Marketing Authorization Holder for Priligy until Marketing … Continue reading →

Posted in Premature Ejaculation | Comments Off

Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

Posted: Published on May 15th, 2012

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award. The Scholarship Foundation of Santa Barbara will honor Fred Gluck and four other outstanding companies and individuals at the South Coast Business & Technology Awards dinner on June 14, 2012 at Fess Parkers Doubletree Resort in Santa Barbara, California. Now in its 18th year, the South Coast Business & Technology Awards was designed to honor individuals and organizations who have demonstrated an extraordinary commitment to helping the South Coast of Santa Barbara County remain economically vital. Fred Gluck is a Brooklyn boy who has enjoyed a variety of careers including butcher boy, check clearing (nights), magazine sales (Catholic Home Messenger), ballistic missile defense, top management consulting, health care delivery, and engineering and construction. Since moving to Santa Barbara in 1998 with his wife, Linda, Fred has been active in various community service roles (Cottage Hospital System, UCSB Foundation, Kavli Institute of Theoretical Physics) and as an entrepreneur in … Continue reading →

Posted in Cell Medicine | Comments Off

Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

Posted: Published on May 15th, 2012

Posted in Cell Medicine | Comments Off

Parcell Laboratories Honored as 2012 SBANE Innovation Award Winner

Posted: Published on May 15th, 2012

NEWTON, Mass., May 14, 2012 /PRNewswire/ --Parcell Laboratories, a leading adult stem cell company based in Newton, MA, was awarded the prestigious 2012 Innovation Award by the Smaller Business Association of New England (SBANE). Parcell joins the select list of winning companies from the last 26 years whose innovations have delivered proven value to customers. SBANE uses its highly competitive Innovation Awards program to showcase technology driven enterprises that are potentially "game changers" in their markets. Parcell's ELA stem cell technology is a platform technology that has unlimited applications for tissue regeneration and is positioned to change the face of regenerative medicine. "We are honored to have been recognized by SBANE for our accomplishments and to be included among the roster of extremely successful companies that have been previous winners of the award," said Pamela Layton, the CEO of Parcell Laboratories. "The award is a testament to the dedication and tenacity of our terrific team." Past award winners include some of the most recognizable names in New England business, including Staples, Genzyme, Ben & Jerry's and Nantucket Nectars. Parcell Laboratories holds the license and intellectual property to the ELA stem cell, which is considered to be the earliest lineage adult … Continue reading →

Posted in Cell Medicine | Comments Off

VistaGen CEO Issues Update Letter to Stockholders

Posted: Published on May 15th, 2012

SOUTH SAN FRANCISCO, CA--(Marketwire -05/14/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA) (VSTA.OB), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockholders and the investment community from its CEO, Shawn Singh. To our valued Stockholders: Since becoming a public company one year ago, we have progressed to perhaps the most exciting time in our company's 14-year history. To arrive at this point, more than $45 million, obtained through various strategic collaborations, investments and grant awards, has been carefully employed. We believe our pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, combined with the network of strategic relationships we have announced, will allow us to secure additional capital and the large market drug rescue opportunities that can deliver value to our stockholders. Since the beginning of the year, our team has carefully reviewed our Top 10 drug rescue opportunities and narrowed our focus to our Top 5 candidates. Now we intend to launch our initial drug rescue program and secure strategic capital necessary to support it, as well as launch our second drug rescue program by year-end. We also are working on validation of LiverSafe 3D, our bioassay system for … Continue reading →

Posted in Cell Medicine | Comments Off

Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives

Posted: Published on May 15th, 2012

DENVER, May 14, 2012 /PRNewswire/ -- Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced that it has secured a $2M investment from philanthropist, visionary and businessman John C. Malone, PhD, chairman of Liberty Media Corporation. In addition to advancing Regenerative Sciences' clinical and lab-based stem cell research, the investment will help support the national expansion of their Regenexx Physician Network. Regenerative Sciences' Regenexx procedures utilize a patient's own stem cells to help repair a broad range of common injuries and degenerative conditions, including cartilage lesions, torn ligaments and tendons, osteoarthritis and bulging spinal discs. For many, the procedures offer a viable alternative to arthroscopic surgery, open-joint surgery, or joint replacement surgery. Regenexx patients experience little or no downtime from the procedures and avoid the lengthy rehabilitation period associated with most surgical procedures. "We are proud of our accomplishments in the field of regenerative interventional orthopedics and it's exciting that our work has drawn the attention of such a noted entrepreneur and philanthropist," said Christopher J. Centeno, M.D., Chief Executive Officer of Regenerative Sciences. "Dr. Malone shares our vision for forging the next generation of minimally invasive regenerative treatments. This investment … Continue reading →

Posted in Cell Medicine | Comments Off

Monthly Archives: May 2012

Categories

Archives